具有受控药物释放,滑和粘附能力的酶响应微凝用于骨关节炎减弱
Keyu Chen1, Jiachen Wang2, Jue Cao1
1Division of Orthopaedic Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Acta biomaterialia
|October 20, 2024
概括
一种新型的氨酸微凝可以在需要时为骨关节炎治疗提供赛莱科西布. 这种药物输送系统增强了关节滑和保持,为骨关节炎提供了一个有前途的新疗法.
科学领域:
- 生物医学工程 生物医学工程
- 药物输送系统 药物输送系统
- 骨关节炎治疗药物 治疗药物
背景情况:
- 骨关节炎 (OA) 治疗受到药物保留不良和快速清除的阻碍,导致不理想的结果.
- 现有的本地药物输送系统在不受控制的释放和短暂的停留时间方面扎.
- 需要先进的输送平台,以确保持续的药物释放和在关节中延长治疗效果.
研究的目的:
- 开发一种基于氨酸 (HA) 的新型微凝,用于在骨关节炎中持续和有针对性地输送赛莱科西布 (CXB).
- 将微凝与酶响应链接器进行工程设计,以便在需要时释放药物,并将软骨结合进行增强的保留和滑.
主要方法:
- 开发了甲基酸盐交叉链接的HA微凝,通过对金属蛋白酶-2 (MMP-2) 响应的链体 (GGPLGLAGGC) 与赛莱科克西布结合.
- 在微凝表面上嵌入了一种原II结合 (CBP),用于软骨附着.
- 在OA大鼠模型中评估了微凝的药物释放,保留时间,抗炎作用,冠状腺保护性质和滑性.
主要成果:
- 响应MMP-2的链接器有助于在OA关节中持续和按需释放赛莱科西布.
- CBP部分增强了软骨结合,导致延长了长达18天的保留时间.
- 微凝有效抑制了巨细胞的激活,减少了促炎性细胞因子,保护了软骨细胞,并减少了软骨的磨损.
结论:
- 开发的酶反应,软骨结合HA微凝为骨关节炎治疗提供了一个有前途的平台.
- 这种先进的药物输送系统证明了长时间的保留,持续的药物释放和增强的滑,提高了治疗疗效.
- 在临床前的模型中,微凝系统有效地减轻了骨关节炎,突出了其作为新型生物医学的潜力.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...